Tucker Asset Management LLC Buys 4,639 Shares of Bristol-Myers Squibb (NYSE:BMY)

Tucker Asset Management LLC raised its position in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 3,313.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,779 shares of the biopharmaceutical company's stock after acquiring an additional 4,639 shares during the quarter. Tucker Asset Management LLC's holdings in Bristol-Myers Squibb were worth $270,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of BMY. United Bank lifted its position in shares of Bristol-Myers Squibb by 2.7% in the third quarter. United Bank now owns 17,322 shares of the biopharmaceutical company's stock valued at $896,000 after buying an additional 456 shares during the last quarter. CreativeOne Wealth LLC lifted its holdings in Bristol-Myers Squibb by 27.5% during the 3rd quarter. CreativeOne Wealth LLC now owns 33,692 shares of the biopharmaceutical company's stock valued at $1,743,000 after purchasing an additional 7,272 shares during the last quarter. Public Sector Pension Investment Board boosted its position in Bristol-Myers Squibb by 13.3% during the third quarter. Public Sector Pension Investment Board now owns 88,350 shares of the biopharmaceutical company's stock worth $4,571,000 after purchasing an additional 10,400 shares during the period. Northwest & Ethical Investments L.P. increased its holdings in shares of Bristol-Myers Squibb by 21.1% in the third quarter. Northwest & Ethical Investments L.P. now owns 16,168 shares of the biopharmaceutical company's stock valued at $837,000 after purchasing an additional 2,820 shares during the last quarter. Finally, Providence Wealth Advisors LLC raised its position in shares of Bristol-Myers Squibb by 2.5% in the third quarter. Providence Wealth Advisors LLC now owns 30,817 shares of the biopharmaceutical company's stock valued at $1,625,000 after purchasing an additional 763 shares during the period. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Bristol-Myers Squibb Price Performance

NYSE:BMY traded down $1.46 during trading hours on Tuesday, hitting $59.53. The company's stock had a trading volume of 9,603,465 shares, compared to its average volume of 12,731,569. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. The stock has a fifty day simple moving average of $58.64 and a 200-day simple moving average of $56.44. The company has a market capitalization of $121.13 billion, a P/E ratio of -13.47, a PEG ratio of 2.07 and a beta of 0.43.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. On average, analysts anticipate that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Friday, April 4th will be issued a $0.62 dividend. The ex-dividend date is Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a yield of 4.17%. Bristol-Myers Squibb's payout ratio is presently -56.11%.

Insider Buying and Selling at Bristol-Myers Squibb

In other news, EVP Samit Hirawat acquired 1,823 shares of the stock in a transaction dated Friday, February 14th. The stock was bought at an average price of $54.84 per share, with a total value of $99,973.32. Following the completion of the purchase, the executive vice president now directly owns 63,932 shares of the company's stock, valued at $3,506,030.88. This represents a 2.94 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.09% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently commented on BMY. Bank of America reiterated a "neutral" rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a research note on Tuesday, December 10th. Truist Financial upped their target price on Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a "buy" rating in a research report on Wednesday, January 8th. Cantor Fitzgerald lifted their price target on Bristol-Myers Squibb from $50.00 to $55.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Citigroup boosted their price target on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a research note on Tuesday, January 28th. Finally, Jefferies Financial Group upgraded Bristol-Myers Squibb from a "hold" rating to a "buy" rating and increased their price objective for the stock from $63.00 to $70.00 in a research report on Monday, December 16th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating, four have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $57.86.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.